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Cryo-EM structure of the human ferritin–transferrin
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Human transferrin receptor 1 (CD71) guarantees iron supply by endocytosis upon binding of
iron-loaded transferrin and ferritin. Arenaviruses and the malaria parasite exploit CD71 for
cell invasion and epitopes on CD71 for interaction with transferrin and pathogenic hosts were
identified. Here, we provide the molecular basis of the CD71 ectodomain-human ferritin
interaction by determining the 3.9 Å resolution single-particle cryo-electron microscopy
structure of their complex and by validating our structural findings in a cellular context. The
contact surfaces between the heavy-chain ferritin and CD71 largely overlap with arenaviruses
and Plasmodium vivax binding regions in the apical part of the receptor ectodomain. Our data
account for transferrin-independent binding of ferritin to CD71 and suggest that select
pathogens may have adapted to enter cells by mimicking the ferritin access gate.
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Human transferrin receptor 1 (CD71 or hTfR1) is a pro-miscuous and ubiquitously expressed cell entry carrierwhose primary function is to import iron in response to
variations in intracellular concentration of this essential element.
Iron uptake is mediated by the internalization of the transferrin
(Tf)–iron complex through receptor-mediated constitutive
endocytosis via a clathrin-dependent pathway1. Once the iron
cargo is delivered, the receptor is recycled back to the cell surface
and apo-Tf is released into the bloodstream2. CD71 has been also
shown to mediate the uptake of heavy-chain ferritin (H-Ft) from
serum as an alternative or additional source of bioavailable iron3.
CD71 is also a preferred entry carrier for human pathogenic
arenaviruses4–8 and hepatitis C virus9, as well as feline-specific
and canine-specific parvoviruses10. Viral systems recognize epi-
topes on the host-encoded CD71 receptor through their surface
spike glycoproteins, allowing the internalization of the complex.
Recently, Plasmodium vivax, the most common malaria parasite,
was demonstrated to access reticulocyte cytoplasm by recognizing
the same CD71 receptor epitope as arenaviruses11,12.
CD71 is a homodimeric type II transmembrane protein com-
posed of a small cytoplasmic domain, a single-pass transmem-
brane region, and a complex extracellular domain. Each
monomer of the ectodomain is subdivided in a protease-like
domain in contact with the cell membrane, a helical domain
comprising the dimer contact regions, and an apical domain
(Fig. 1a)13. The ectodomain displays ligand-binding sites for
diverse proteins: its basal portion (formed by the protease-like
and the helical domains) binds Tf14–16 and the dimer interface
region forms a complex with the hereditary hemochromatosis
factor (HFE)17 (Fig. 1b). The upper part of the apical domain has
been shown to interact with arenaviruses4,8 and with the P. vivax
invasion protein PvRBP2b12 (Fig. 1b).
In this framework, a key missing piece of information concerns
the structural basis of the interaction between CD71 and H-Ft.
Experimental evidence was provided for a scarce competition
between ferritin and Tf for CD71 binding, thus pointing out the
possibility of the existence of different epitopes for the two pro-
tein ligands3,18. Recently, an exposed loop region in the H-Ft
subunit was identified that, transplanted in an archaeal ferritin,
originally unable to recognize the human CD71 receptor, was
sufficient to induce binding of this chimeric protein to the
receptor19.
The importance of the CD71/H-Ft interaction is dictated by
the emerging physiological and pathological significance of the
circulating ferritin and its scavenger receptor20,21. Moreover,
nano-sized H-Ft homopolymers have moved to the center stage
of nanomedicine research as theranostic agents22, due to their
unique cargo capabilities for small therapeutic molecules or iso-
topic tracers coupled to selectivity towards CD7123–25. CD71 is
highly expressed in the most common cancer cell types, further
highlighting the interest for this receptor as a privileged target for
the selective delivery of cytotoxic drugs coupled to Tf, ferritin, or
monoclonal antibody drug conjugates26–28.
We used single-particle cryo-electron microscopy to solve the
structure of H-chain ferritin bound to human CD71 ectodomain
to 3.9 Å resolution, unveiling the structural determinants that
govern their recognition.
Results and discussion
H-Ft binds the CD71 receptor in a virus-like fashion. H-Ft
binds the CD71 receptor through four specific contact regions on
the apical domain, covering an overall area of ~1900 Å2 (Fig. 2,
Supplementary Figures 1–3 and Supplementary Table 1). As
depicted in Fig. 2, the four contact regions comprise: (i) a motif of
six amino acids, from R208 to L212 and N215 on the βII-2 strand;
(ii) residues E343, K344, and N348 on the αII-2 helix. We refer to
these residues as “common contacts” on CD71, since they
represent the key structural determinants for binding of arena-
virus (MACV) and plasmodial PvRBP2b proteins. Additionally,
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Fig. 1 CD71 receptor: ligand recognition epitopes and binding modes. CD71 homodimer is shown in ribbon representation (pdb 3KAS8). One monomer is in
light gray, the other is colored variably to the receptor domains (apical, light blue; protease-like, yellow; helical, green). a CD71 residues identified as
recognition epitopes for Tf/HFE and viruses/parasite are represented as orange/wheat and red/pink surfaces, respectively. b CD71 receptor is shown
bound to Tf (orange surface, pdb 1SUV14), HFE (cyan surface, pdb 1DE417), GP1 protein of MACV (pink surface, pdb 3KAS), and Tf (orange surface) and
PvRBP2b from P. vivax (blue surface, pdb 6D0412)
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“exclusive contact” regions on CD71 for H-Ft comprise (iii) the
βI-1–βII-1 loop and the βII-1 strand (S195, E197, S199, and I202)
and (iv) the βII-8 strand (K374). The H-Ft-binding counterpart
regions are: (i) the external BC loop (R79, F81, Q83, K86, K87);
(ii) the N-terminus of the A-helix (Q14, D15, E17-A19, N21, R22,
N25); (iii) the C-terminus of the C helix (E116, K119, D123)
(Fig. 2).
The H-Ft “exclusive contacts” pairwise interactions are shown
in Fig. 2b and c, where: (i) CD71 βII-1 strand contacts H-Ft via
the A helix; (ii) βI-1–βII-1 loop interacts with the H-Ft C helix;
(iii) K374 on βII-8 of CD71 electrostatically interacts with Q14 at
the beginning of H-Ft A helix.
The “common contacts” with CD71, shared between pathogens
and H-Ft, are shown in Fig. 2d and are established by the βII-2
strand of CD71 with the H-Ft A helix, BC loop, and C helix, and
with T5 at the H-Ft N-Terminus. Further common interactions
are established between the CD71 αII-2 and H-Ft A helix, the BC
loop and K87 on the BC loop of a flanking H-Ft monomer
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Fig. 2 Structure of the human CD71/H-Ft complex. a Atomic model of the complex of human CD71 receptor (yellow) and human H-Ft (light blue) fitted in
the cryo-EM map at a global resolution of 3.9 Å (gray mesh) is shown. On the side, close-up view of the contact region. The interacting residues of CD71
are highlighted by different colors depending on the specific secondary structural element of the apical domain to which they belong. Interacting residues of
H-Ft are colored in light blue. b–e CD71 and H-Ft interacting regions. Panels b and c show the “exclusive contacts”; panels d and e show the “common
contacts”. Contacting residues within 5 Å distance are shown in sticks, labeled and colored according to the color code used for secondary structure in
panel a (right side). Dashed black lines indicate electrostatic interactions. Dotted gray lines represent hydrophobic contacts. f Surface representation of the
human CD71 apical domain (dark gray). Ligand specific and overlapping residues contacted by the human H-Ft, GP1 of Machupo virus8 and PvRBP2b of P.
vivax12 are mapped out following the color code shown at the bottom
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(Fig. 2e; the detailed contacts are given in Supplementary
Table 2).
Notably, the amino acids involved in “common contacts”
coincide with amino acids on CD71 that lead to gain or loss of
interaction with pathogen-binding proteins upon mutations12,29
(Fig. 2f and Supplementary Table 3). These cluster in the βII-2
and αII-2 regions, which appear to be essential on CD71 for
binding with various partners. Therefore, in order to identify the
determinants on H-Ft for binding to CD71 we selected and
mutated H-Ft residues involved in “common contacts” which are
not conserved in ferritins shown to be unable to bind human
CD71, i.e. human Light-chain ferritin3 (Hum L-Ft or L-Ft) and
Archeoglobus fulgidus ferritin19 (AfFt) (Supplementary Figure 4).
Mutations at common contacts tune ferritin–CD71 interac-
tion. We produced three multiple mutants of residues peculiar of
human H-Ft: (i) mutant A lacking the polar residues at the N-
terminal of the A helix (Q14A/D15A/R22A), (ii) mutant B
lacking F81 and Q83 on the external BC-loop (F81A/Q83A), and
(iii) mutant C that combines A and B mutations (Q14A/D15A/
R22A/F81A/Q83A) (Supplementary Figure 4). Surface plasmon
resonance (SPR) measurements using wild-type or mutant H-Fts
as analytes and CD71 as ligand showed that the binding affinity
for the receptor is reduced of about two orders of magnitude in
mutants A and B as compared to the wild type, and abolished in
mutant C (Fig. 3a, Supplementary Tables 4 and 5). In particular a
critical drop of the kon value is increased across mutants B and C,
suggesting that mutations at the BC loop have a dominant role in
impairing the CD71/H–Ft interaction, likely due to the loss of
contact of F81 and Q83 with Y211 on CD71 βII-2 and Q83 with
N348 on CD71 αII-2. Consistently, fluorescence-activated cell
sorting (FACS) (Fig. 3b, Supplementary Figure 5) and confocal
microscopy (Fig. 3c) measurements on HeLa cells uptake of the
three H-Ft mutants show reduced (mutant A) or negligible
(mutants B and C) internalization with respect to the wild type.
All together, these results assess the critical relevance of ferritin
external BC-loop in CD71 binding, recognizing the “common
contact” residues Y211 and N348, crucial for binding of viruses and
plasmodial proteins, whose mutations severely hamper binding and
suppress internalization. However, they also highlight the relevance
of Q14, D15, and R22 at the N-terminus of the A helix.
Therefore, the significant binding capability of the humanized
A. fulgidus ferritin (Hum-AfFt) where the human H-Ft BC loop
had been transplanted, is likely due not only to the presence of
F81 and Q83 on the loop, but also to R22 on the A helix,
serendipitously present in this archaea ferritin.
Notably, Hum L-Ft, which is unable to bind CD713, presents
differences in seven positions (S5, T14, S22, L81, D116, A119,
A123) over the total contacts required for the recognition of the
receptor (Supplementary Figure 4a). We found that L-Ft to H-Ft
mutations at these positions (mutant D) confer binding capability
to CD71 with an affinity similar to the one observed for H-Ft
(Supplementary Figure 6).
Significance of CD71 apical domain. In this work, we identified
the specific sites on CD71 to be hooked by H-ferritin for
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Fig. 3 Characterization of human H-Ft wild type and mutants binding to CD71. a SPR sensograms of the interaction between the immobilized his-tagged
CD71 receptor and H-Fts (wild-type and mutants), used as analytes. Fits are reported as black lines. Source data are provided as a Source Data file. b
Ferritins uptake in HeLa cells has been quantified by flow cytometry. The percentage of cells internalizing AfFt-FITC (here used as negative control19), H-Ft-
FITC, MutA-FITC, MutB-FITC, and MutC-FITC is shown as mean ± s.e.m. for n= 3 independent experiments. Source data are provided as a Source Data
file. c Internalization of ferritins in HeLa cells observed at a ×60 confocal microscope, here shown as single FITC and overlay images with phase-contrast.
Scale bars: 10 µm
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physiological access to cell through the CD71 “iron door”. Our
results show that even a single subunit of H-chain over 24 can be
recognized by CD71 and this might be sufficient to favor the
cellular internalization of the mixed H/L-chain 24-mer ferritin
through this route of access, even though in serum the L-chain is
prevalent30. Moreover, we provide structural evidence that Tf and
ferritin exploit alternative epitopes on the same receptor, allowing
differential regulation of iron, as in the case of the HFE3,17.
Importantly, pathogens have adapted to exploit the ferritin
epitope to unlock cellular barriers by mimicking this physiolo-
gical interaction with the CD71 apical domain. In this framework,
changes due to single nucleotide polymorphisms (SNPs) within
the CD71 apical domain may account for permissivity of virus or
parasite entry, but cannot be considered neutral with respect to
ferritin uptake. Along this line, CD71 species-specific variants
must conveniently be matched to H-Ft co-evolved variants in
order to conserve the physiological functions of serum circulating
ferritin.
In conclusion, our work provides a sound structural basis to
elaborate on the possibility of developing alternative ferritin-like
anti-viral or anti-parasite therapeutic ligand, be it an antibody or
a peptidomimetic capable of blocking the “common contacts”
epitope on CD71 residue, and to further engineering ferritins as
theranostic agents.
Methods
Cloning expression and purification of human H-Ft and CD71. The genes
encoding the human apo-H-chain ferritin (H-Ft), mutants A (Q14A/D15A/R22A),
B (F81A/Q83A), human apo-L-chain ferritin (Hum L-Ft or L-Ft) and its mutant D
(S5T/T14Q/S22R/L81F/D116E/A119K/A123D following H-Ft numbering), and
Archaeoglobus fulgidus ferritin (AfFt) were designed, synthesized, optimized for
Escherichia coli codon usage and cloned in pET11b vector by Geneart (Geneart
AG) (Supplementary Table 6). Mutant C was produced by using the Quick Change
Lightning Kit (Agilent Technologies, Santa Clara, CA, USA) according to the
manufacturer’s instructions and using mutant A as template (Supplementary
Table 6). All apo-H-Ft variants, L-Ft expression, and purification were performed
as reported by Falvo et al.27, yielding about 90 and 40 mg of pure protein per litre
of bacterial culture, respectively, for the H-ferritins and for the L-ferritin. Briefly, E.
coli BL21 (DE3) cells harboring recombinant plasmids were grown to OD600 0.6 at
37 °C in 1 L of ampicillin-containing Terrific Broth (TB) medium. Gene expression
was induced by addition of 0.5 mM isopropyl-1-thio-ß-D-galactopyranoside
(IPTG) and cells were further grown at 22 °C overnight. After cell harvesting, pellet
was suspended in 50 mM Tris–HCl, 0.5 mM dithiothreitol (DTT), 1 mM ethyle-
nediamine tetra-acetic acid (EDTA), and 300 mM NaCl, pH 7.5, and disrupted by
sonication in the presence of 1 mM phenylmethylsulfonyl fluoride (PMFS). The
lysate was centrifuged and the supernatant containing the soluble fraction was
treated 40 min at 37 °C with 0.1 mg/mL DNase supplied with 10 mM MgCl2,
heated to 55 °C for 8 min, and then centrifuged to remove denatured proteins. The
recovered supernatant was heated a second time to 72 °C for 8 min, and then
centrifuged. The recovered supernatant was precipitated in 75% ammonium sul-
fate. The pellet was resuspended and dialyzed overnight against phosphate-buffered
saline (PBS) pH 7.5 and then loaded onto a HiTrap Q HP column (Q Sepharose
High Performance GE Healthcare, Boston, USA). The recovered samples were
ultracentrifugated at 35,000 rpm for 55 min at 6 °C using a Beckman L8-70M
ultracentrifuge (Beckman Coultier). The recovered supernatant was then pre-
cipitated using ammonium sulfate at 65% saturation. The pellet was resuspended
and dialyzed overnight against PBS pH 7.5, pooled, concentrated, and sterile-
filtered before storing at 4 °C. The L-Ft mutant D had low purification yield due to
a high fraction of expressed protein being lost in the inclusion bodies. Purity was
assessed by SDS–PAGE; protein concentration was determined spectro-
photometrically at 280 nm using a molar extinction coefficient (on a 24-mer basis)
of 4.56*105 M−1 cm−1 (ProtParam sofware, http://www.expasy.org). In order to
assess the 24-mer assembly of all the produced ferritin variants, size exclusion
chromatography (SEC)-HPLC experiments were performed on samples at 2 mg/
mL concentration, using a Superose 6 gel-filtration column equilibrated with PBS
at pH 7.4 (Supplementary Figure 4b). Traces were analyzed with Origin 8.0
(Originlab Corporation, Northampton, MA).
AfFt expression was performed in E. coli BL21 (DE3) and induced with 1mM
IPTG at OD600= 0.6. After 3 h at 37 °C cells were harvested by centrifugation. Pellet
was resuspended in a lysis buffer containing 20mM HEPES, pH 7.5, 200mM NaCl,
1mM TCEP (tris(2-carboxiethyl)phosphine), and a cOmplete™ Mini Protease
Inhibitor Cocktail Tablet (Roche). Cells were disrupted by sonication and the soluble
fraction was purified by heat treatment at 80 °C for 10min, followed by centrifugation
(15,000 rpm at 4 °C for 1 h). The soluble protein was further purified by ammonium
sulfate precipitation. The precipitated fraction at 70% ammonium sulfate was
resuspended in 20mM HEPES, 50mM MgCl2, pH 7.5 and dialyzed versus the same
buffer. SEC was then performed using a HiLoad 26/600 Superdex 200 GL column
previously equilibrated in the same buffer. Sample purity was estimated by SDS–PAGE
and protein concentration was calculated spectrophotometrically using an extinction
coefficient at 280 nm of 33,900M−1 cm−1. Protein yield was ∼40mg L−1 culture31.
The gene encoding the ectodomain of human CD71 (residues 121–760) was
extracted by pcr from the plasmid pAcGP67A-TfR32 (Addgene, Cambridge, MA)
and BamHI/EcoRI inserted using the Gibson cloning method and fused at the 3′ of
the Kozak sequence of the pα−H mammalian expression vector modified by the
addition of the hydrophobic leader peptide from the baculovirus protein gp67
(pα−H BiP). An octa-histidine tag was also placed at the C-terminus of the CD71
gene. The expression plasmid pα−H BiP/TfR1 was transiently transfected in HEK
293 using polyethylenimine (PEI) as transfection agent. Cells were grown in
FreeStyle 293 expression media (ThermoFisher Scientific, Hampton, USA)
supplemented with 1% of fetal bovine serum (FBS) at 37 °C in a humidified
atmosphere of 5% CO2. After 96 h, cells were harvested and CD71 was purified
from supernatants using Ni-affinity or Co-affinity chromatography. Supernatant
was filtered and incubated with the resin after addition of 50 mM sodium
phosphate buffer, pH 8.0, together with 200 mM NaCl and 20 mM imidazole; 250
mM imidazole was used to elute CD71. The protein sample was stored at −80 °C in
50 mM sodium phosphate, 200 mM NaCl, pH 8. Quality and quantity of purified
protein was evaluated by SDS–PAGE and UV/visible spectra using the theoretical
ε280 nm 96,260M−1 cm−1.
CD71/H-Ft complex preparation. In vitro, incubation of H-Ft and CD71 at dif-
ferent stoichiometric ratios results in protein aggregation due to the presence of
multiple binding sites on both H-Ft and CD71, forming insoluble precipitates. We
managed to isolate a soluble sample of CD71/H-Ft complex by means of a pull-
down experiment3. Two hundred and fifty micrograms of 8xHis-tag-fused CD71
was incubated with 100 μL of TALON resin (TALON Superflow Metal Affinity
Resin, Ge Healthcare, UK) in 25 mM Tris–HCl, 150 mM NaCl, 1% PEG 8000, and
10 mM Imidazole, pH 7.2 (buffer A), for 60 min at 4 °C, under rotation. After
several washes with buffer A, CD71-conjugated beads were incubated with 950 μg
of H-Ft for 90 min at 4 °C under rotation. The beads were washed increasing
imidazole concentration in buffer A up to 30 mM, and the complex was eluted in
350 μL using 290 mM imidazole in buffer A. As a control experiment, CD71-
unconjugated beads were also incubated with 950 μg of H-Ft for 90 min, following
the same procedure adopted to isolate the complex. The pull-down assay final
samples were analyzed by SDS/PAGE (Supplementary Figure 1a).
Grids preparation for cryo-electron microscopy. The CD71/H-Ft complex eluted
from Talon resin at a concentration of 0.2 mg/mL in 25 mM Tris–HCl, 150 mM
NaCl, 1% PEG 8000, and 290 mM Imidazole, pH 7.2 was used for grid preparation
immediately after the pull-down experiment, without buffer exchange and sample
concentration. Two datasets were collected using the same batch of grids to obtain
the final map.
Holey-gold R0.9/1 (dataset 1) and holey-carbon R1.2/1.3 (dataset 2) grids
(Quantifoil Micro Tools GmbH) covered by 2 nm film of carbon were prepared as
described33. Grid surfaces were treated with plasma cleaning using a mixture of Ar
and O2 for 60 s before applying 3 μL of sample. The screening of several blotting
conditions revealed that the time between sample application to the grid and
plunge into ethane affects the number of particles per field and their distribution.
The dataset 1 grid was prepared with a 135 s wait time and the dataset 2 grid with a
90 s wait time. Grids were then blotted for 1 s (100% humidity, 4 °C, force 4) with
filter paper and vitrified by rapidly plunging into liquid ethane at −180 °C using a
Vitrobot Mark IV (FEI, Hillsboro)34.
Data collection. The first dataset (dataset 1, 690 micrographs, Supplementary
Figure 3) was imaged using a FEI Titan Halo (ThermoFisher Scientific, Eindhoven)
operating at 300 kV acceleration voltage, while the specimen was maintained at
liquid nitrogen temperature using a Gatan 626 side entry cryo-holder (Gatan,
Pleasanton). Images were recorded using the automated acquisition program
Leginon35. We used a Gatan K2 Summit direct-detector camera (Gatan, Pleasanton)
operating in counting mode, with a calibrated pixel size of 1.15 Å on the object scale.
Images were typically recorded with a defocus range between −0.7 and −3.0 μm.
Movies were acquired with a total exposure time of 12 s (60 frames/image), with
exposure rate of 7.8 electrons/pix/s.
A second dataset (dataset 2, 573 micrographs, Supplementary Figure 3) was
imaged using a 300 kV Titan Krios (ThermoFisher Scientific, Eindhoven). The
dataset was collected automatically using EPU (ThermoFisher Scientific,
Eindhoven). Images were recorded on a Gatan K2 Summit direct-detector camera
(Gatan, Pleasanton) equipped with a Gatan Bioquantum LS/967 energy filter and
operating in super-resolution mode, using a calibrated pixel size of 1.33 Å on the
object scale. Images were typically recorded with a defocus range between −1.0 and
−3.0 μm. Movies were acquired in electron counting mode, the total exposure time
was set to 12 s (40 frames/image), with exposure rate of 6.2 e−/pix/s.
Image processing. The main steps of data analysis are schematized in the
workflow shown in Supplementary Figure 3.
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Micrograph frames collected in both datasets (Supplementary Figure 1b) were
aligned for beam-induced motion correction and drift with MotionCor236; global
contrast transfer function was calculated using Gctf37. Micrographs with resolution
limits ≤6 Å (dataset 1) or ≤5 Å (dataset 2) were kept for further processing.
All subsequent data analysis was carried out using RELION 2.038. More than
1100 particles for both datasets were manually picked to produce a reference for
the automated particle picking procedure implemented in RELION39. A total of
140,567 and 194,501 particles were automatically picked, respectively, from dataset
1 and dataset 2 and extracted from the original micrographs. After the extraction,
particles were initially classified in 2D using K= 100 classes. A second round of 2D
classification was performed on each dataset with K= 25 classes. The best 2D class
averages clearly showed the CD71/H-Ft complex in different orientations, revealing
some extent of sample heterogeneity due to the presence of alternative populations
endowed with different stoichiometry (Supplementary Figure 1c). A set of 27,690
particles, belonging to good 2D classes of dataset 1, was selected and subjected to a
first round of 3D classification, using eight classes and without imposing any
symmetry; the cryo-EM apo-ferritin map (EMDB code EMD-278833) was used as
reference model, filtered at 60 Å. This procedure gave only one class (8860
particles) where a 1:1=H-Ft:CD71 complex was clearly displayed. The resulting
map was used as reference (filtered at 60 Å) to run a second round of 3D
classification, which resulted in two better-resolved classes (total 17,370 particles).
These classes (see Supplementary Figure 3) were selected for further refinement
using the 3D Autorefine procedure, applying a spherical mask of 290 Å diameter.
This resulted in a map at 8.2 Å resolution.
The reconstructed map of dataset 1 (filtered at 40 Å) was used as reference
model for the 3D classification of particles selected from 2D classification of dataset
2 (73,700 particles). Good classes (Supplementary Figure 3) were selected for
further refinement using the 3D Autorefine procedure (25,870 particles, spherical
mask of 290 Å diameter), which yielded a map at 5.5 Å resolution.
With the aim to further increase the resolution of the contacting region between
the two molecules, particles used for the 3D refinement of both datasets were
joined (total 43,240 particles) and subjected to one round of 3D refinement,
imposing O symmetry (i.e., ferritin point-group symmetry) and applying a smaller
mask diameter of 180 Å, to only include the ferritin molecule. This yielded a 4.8 Å
map of ferritin re-centered to its center of symmetry (Supplementary Figure 3). We
used the corresponding particle alignment parameters to perform symmetry
expansion of this dataset using RELION (relion_particle_symmetry_expand). This
allowed us to subdivide ferritin particles in individual subunits in order to identify
by classification all ferritin subunits bound to a Tf receptor40. The dataset was thus
artificially expanded according to the pseudo-symmetric O point group and
enlarged 24-fold, resulting in 1,037,760 particles, that were 3D Classified using
C1 symmetry, no image alignment and a mask generated from the complex with a
single receptor bound. This classification round identified all subunits bearing a
receptor bound. All four classes generated were subjected to a second round of 3D
classification, this time with local image alignment, and only two of them allowed
the identification of subclasses of ferritin bound to the receptor. Therefore, three H-
Ft bound subclasses were combined (total 53,878 particles) and refined. After
postprocessing, the resolution measured using a mask (9 pixel extension, 24 pixel
soft edge) only including ferritin and the receptor contact sites was estimated to be
4.4 Å resolution (Supplementary Figure 2d).
The refined particles were exported into cisTEM to perform per-particle
defocus refinement procedure implemented in cisTEM41. The resulting final map
resolution of H-Ft and CD71 was improved up to 3.9 Å, clearly showing secondary
structures and bulky side chains of interacting residues, which allowed more
precise model building. Statistic information of the 5.5 Å and of the 3.9 Å density
maps is reported in Supplementary Table 1.
Resolution estimation. The overall resolution of the two maps at 5.5 and 4.4 Å
obtained with RELION and the one at 3.9 Å obtained with cisTEM (Supplementary
Figure 2a, c and e, f) was estimated with the Fourier shell correlation (FSC)= 0.143
criterion, based on the ‘gold-standard’ protocol42 using a mask around the complex
density. To estimate the resolution at the CD71/H-Ft interacting region we applied
a spherical mask, created with Chimera43, only including this portion. The reso-
lution is 3.9 Å based on the gold-standard 0.143 FSC criterion (Supplementary
Figure 2g). The input maps were corrected for the modulation transfer function
(MTF) of K2 detector and sharpened using negative temperature B factors as
estimated by RELION (Supplementary Table 1). Local resolution was measured for
the map at 5.5 and 4.4 Å using ResMap44 (Supplementary Figure 2b and d). The
electron density maps obtained at 5.5 and at 3.9 Å resolution were sharpened using
autosharpen in Phenix45. UCSF Chimera43 and PyMOL (http://pymol.sourceforge.
net) were used for graphical visualizations.
Model building and refinement. The program Chimera was initially employed to
rigid body fit the crystal structures of H-Ft (PDB code 3AJO46) and CD71 (PDB
code 3KAS8) into the sharpened electron density map obtained at 5.5 Å resolution,
which was further refined as rigid body with Phenix real_space_refinement. In this
map, both CD71 and H-Ft were visible at the level of their secondary structures.
The resulting CD71/H-Ft model was then rigid body fitted into the sharpened 3.9 Å
density map using UCSF Chimera. Model building of H-Ft and of the CD71
contact region was performed manually using Coot47. Given the high quality of the
reconstructed map, the side chains of residues exposed at the contacting interface
were modeled into the electron density (Supplementary Figure 2h).
The model of the CD71/H-Ft complex was refined using the
real_space_refinement routine in minimization global mode (Phenix) against the
overall map at 3.9 Å, imposing secondary structure and Ramachandran restraints.
Final visual inspection was performed in COOT to manually correct
Ramachandran outliers. The final model was validated using MolProbity48 and
EMRinger49 (Supplementary Table 1). All figures were produced using Pymol and
UCSF Chimera.
CD71/H-Ft and CD71/L-Ft SPR assay. The interactions between the immobilized
N-terminal His-tagged Tf receptor CD71 (ligand) and H-Ft-based constructs
(analytes) were measured by SPR technique on a Biacore X100 instrument (Bia-
core, Uppsala, Sweden) according to the procedure previously reported 28. Briefly,
CD71 was immobilized on a Sensor Chip nitrilotriacetic acid (NTA) (GE
Healthcare Europe GmbH) according to the manufacturer’s instructions. The
optimal experimental setup was determined and CD71 was injected at 22 μg/mL
for 60 s for the multi-kinetic mode and up to 30 μg/mL in the single kinetic mode.
For the first mode, analyte concentration was in the range of 1000–62.5 μg/mL. The
sensor chip surface was regenerated using fresh histidine-tagged protein after every
cycle of the assay. The SPR assay was performed at 25 °C, at flow rate= 30 μL/min;
the association and dissociation phases were monitored for 180 and 600 s,
respectively. Analytes were dissolved in degassed 10 mM PBS at pH 7.4. In this
condition H-Ft retains the 24-mer assembly (Supplementary Figure 4b). To
regenerate the chip, complete dissociation of the complexes was achieved by the
addition of 10 mM HEPES, 150 mM NaCl, 350 mM EDTA, and 0.005% (vol/vol)
surfactant P20 (pH 8.3) for 30 s before starting a new cycle. The kon and koff rates as
well as the dissociation constant (KD) were estimated using the Biacore X100
evaluation software according to a 1:1-binding model or alternatively a hetero-
geneous analyte-binding model (Supplementary Tables 4 and 5). All experimental
data shown in Fig. 3a are reported at analyte concentration of 1 mg/mL. Fits are
reported as black lines corresponding to a heterogeneous analyte-binding model for
wild type, Mutant A and Mutant B, respectively, and to a simple 1:1 kinetic model
for Mutant C.
For the single kinetic mode, analyte concentration was in the range of
300–18.75 μg/mL and the sensor chip surface was regenerated using fresh histidine-
tagged protein for all ferritins tested, i.e. wild type H-Ft, L-Ft, and mutant D.
Protein FITC labeling. HFt, AfFt, Mutant A, Mutant B, and Mutant C were labeled
with fluorescein-isothiocyanate (FITC, ThermoFisher) according to the manu-
facturer’s standard protocol. Briefly, 2 mg/mL of the purified protein was added
with 10-fold molar excess of FITC in protein storage buffer, stirring for 2 h at RT.
The non-reacted dye was removed by gel filtration chromatography and the
fluorescent dye to protein ratio was determined by UV spectroscopy. LC–MS
spectrometry measurements of all FITC-conjugated proteins confirmed that >40%
of monomers are FITC labeled.
Cell cultures and ferritins internalization. HeLa cells (ATCC Number: CCL-2)
were grown at 37 °C in Dulbecco’s modified Eagle’s medium with Glutamax
(DMEM, Gibco) supplemented with 10% FBS (Gibco) and 1% Penstrep (100 U/mL
penicillin and 100 μg/mL streptomycin solution; Gibco). DMEM without phenol
red (Sigma) supplemented with Glutamax (Invitrogen), 10% FBS and 1% Penstrep
(incubation medium) was used for apo-ferritins internalization assays by FACS and
confocal microscopy.
Flow cytometry analysis. HeLa cells were seeded on six-well plates and left 1 day
prior performing FACS experiments. Upon growing medium removal and rinse
with PBS, confluent cells were incubated with FITC-ferritin nanoparticles (AfFt,
HFt, Mutant A, B and C as specified in each experiment) at the final concentration
of 30 μg/mL for 2 h 30 min. Cells were then washed twice with PBS, detached with
trypsin-EDTA (Euroclone), rinsed with PBS and resuspended in BD-FACS flow
buffer. Control cells were treated in the same conditions without ferritins. Inter-
nalization of ferritins was evaluated with sample acquisition at the BD LSRFortessa
(BD Biosciences, San Jose, CA, USA) equipped with a 488 nm laser and FACSDiva
software (BD Biosciences version 6.1.3). Live cells were first gated by forward and
side scatter area (FSC-A and SSC-A) plots, then detected in the green channel for
FITC expression (530/30 nm filter) and side scatter parameter. The gate for the
specific signal was set based on the control sample. Data were analyzed using
FlowJo 9.3.4 software (Tree Star, Ashland, OR, USA).
Confocal microscopy of live cells. For apo-ferritins internalization by live ima-
ging on a confocal microscope, HeLa cells were seeded on a μ-slide eight-well
ibiTreat (ibidi) and left 1 day to grow. After the removal of the medium, cells were
washed with PBS and incubated for 20 h with 30 μg/mL FITC-ferritin nanoparticles
(H-Ft, Mutant A, B and C). Prior imaging, cells were washed twice with PBS to
eliminate the unbound FITC-ferritins and then replaced in the incubation medium
(suitable for confocal imaging purposes). The confocal laser-scanning microscope
used was an Olympus FV10i platform equipped with a built-in incubator. Images
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were acquired with a ×60/1.2NA water-immersion objective, LD lasers and filter
sets for FITC. FITC and phase-contrast channels were acquired simultaneously.
Data availability
All data supporting the findings of this study are available within this paper and from the
corresponding authors. The cryo-EM maps of CD71/H-Ft complex at 5.5 Å and at 3.9 Å
and coordinates generated and analyzed in the current study have been deposited in the
Electron Microscopy Data Bank and in the Protein Data Bank under accession code
EMD-0046 (PDB 6GSR) and EMD-0140 (PDB 6H5I), respectively. The source data
underlying Fig. 3a, b and Supplementary Figs. 1a, 5 and 6 are provided as a Source Data
file.
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